Absence Seizures
📧 Sign up to get email alerts when something new happens for Absence Seizures.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures [Phase 2]
This Phase 2 study compares NPT 2042 to placebo in patients aged 16-75 years with genetic generalized epilepsy and absence seizures and is c…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
A completed clinical trial update examining comorbidities in epilepsy using eye movement recordings, with a focus on childhood absence epile…
-
FDA approval · 2025-08-01FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Ethosuximide submitted by PAI Holdings, LLC dba PAI Pharma. The action updates the regulatory st…
-
FDA approval · 2023-05-01FDA Approved: METHSUXIMIDE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' original application for methsuximide, a generic anticonvulsant used to treat absence seizures.
-
FDA approval · 2022-08-25FDA Approved: ETHOSUXIMIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for Ethosuximide submitted by Strides Pharma Science Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for Ethosuximide filed by Epic Pharma, LLC.
-
FDA approval · 2022-02-22FDA Approved: ETHOSUXIMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ethosuximide from Chartwell RX, LLC, indicating regulatory approval of a change to the approved …
-
FDA approval · 2022-02-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Ethosuximide from Bionpharma Inc., indicating regulatory changes were approved for this prod…
-
FDA approval · 2021-10-29FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2021-10-28FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2020-04-01FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Ethosuximide from Bionpharma Inc.
-
FDA approval · 2020-03-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ethosuximide submitted by Chartwell RX, LLC, under the ANDA program.
-
FDA approval · 2020-03-16FDA Approved: ETHOSUXIMIDE — Original Application (Epic Pharma, LLC)
FDA approved Ethosuximide from Epic Pharma, LLC under an Abbreviated New Drug Application. It is approved as a generic treatment for absence…
-
FDA approval · 2019-02-19FDA Approved: ETHOSUXIMIDE — Original Application (Strides Pharma Science Limited)
FDA approves Strides Pharma Science Limited's original ANDA for ethosuximide, a generic treatment for absence seizures in epilepsy.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Magnetoencephalography in Absence Seizures
This update reports the completion of a clinical trial evaluating magnetoencephalography in patients with absence seizures.
-
FDA approval · 2017-05-05FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Ethosuximide (PAI Pharma) to update the product labeling.
-
FDA approval · 2016-05-17FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis Div. of Pfizer Inc., indicating approved changes to the…
-
CLINICAL_TRIALS trial_result · 2016-05-10Clinical Trial Update: Does Body Positioning Affect the Yield of Hyperventilation in Routine Pediatric Electroencephalography - EEG Studies? [NA]
This clinical trial update examines whether body positioning affects the yield of hyperventilation in routine pediatric EEG studies for epil…
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents [Phase 3]
Phase 3 clinical study of lamotrigine for newly diagnosed typical absence seizures in children and adolescents has completed, with results p…
-
FDA approval · 2014-01-16FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc, reflecting an approved m…
-
FDA approval · 2014-01-15FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Ethosuximide from PAI Holdings, LLC dba PAI Pharma.
-
FDA approval · 2014-01-07FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Ethosuximide from Bionpharma Inc. under ANDA040430.
-
CLINICAL_TRIALS trial_result · 2013-09-17Clinical Trial Update: A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures [Phase 2]
A completed Phase 2 safety and efficacy follow-up trial of Levetiracetam in children aged 4-17 with absence seizures.
-
FDA approval · 2012-10-25FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis Div of Pfizer Inc, indicating approval of changes to th…
-
FDA approval · 2012-10-25FDA Approved: CLONAZEPAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for clonazepam from Aurobindo Pharma Limited under an ANDA, confirming continued availability of thi…